WCG Clinical, which provides ethical review services and other clinical trial solutions to biopharmas and CROs, filed on Thursday with the SEC to raise up to $100 million.
WCG believes that it is a leading provider of clinical trial solutions, which enable biopharmaceutical companies, contract research organizations (CROs), and institutions to accelerate the delivery of new treatments and therapies to patients. The company's proprietary suite of technology-enabled solutions provides ethical review services as well as broader clinical trial solutions including study planning and optimization, patient engagement, and scientific and regulatory review services.
The Princeton, NJ-based company was founded in 2012 and booked $498 million in revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol WCGC. Goldman Sachs, Morgan Stanley, BofA Securities, Barclays, Jefferies, William Blair, and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
